Advanced search

Karl-Ludwig Kley is a German businessperson who has been at the head of 7 different companies. He occupies the position of Chairman-Supervisory Board for E.ON SE, Chairman-Supervisory Board for Deutsche Lufthansa AG and Co-Managing Director at Glasbau Hahn GmbH. Dr. Kley is also on the board of Bayerische Motoren Werke AG, Fritz Thyssen Stiftung and Deutsche Akademie der Technikwissenschaften eV and Chairman-Management Board at Baden Badener Unternehmergespräche, Vice President for Bundesverband der Deutschen Industrie e.V., Member-Executive Board at E. Merck KG and Vice President at Verband der Chemischen Industrie eV.
In his past career Dr. Kley was Chairman-Executive Board at Merck KGaA, Head-Corporate Finance & Investor Relations at Bayer AG and Chief Financial Officer at Bayer Holding Ltd. (a subsidiary of Bayer AG), Chairman-Supervisory Board for Lufthansa AirPlus Servicekarten GmbH, Chairman-Supervisory Board of 1. FC Köln GmbH & Co. KGaA, Director-Management Board at KG Allgemeine Leasing GmbH & Co. and Head-Pharmaceutical Division at Bayer SpA.
Dr. Kley received a doctorate, a graduate degree and a graduate degree from Ludwig-Maximilians-Universität München.

Karl-Ludwig Kamprath formerly worked at Deutsche Sparkassen Leasing AG & Co. KG, as Chairman-Supervisory Board, Kreissparkasse München Starnberg Ebersberg, as Chairman, Deutsche Leasing AG, as Chairman-Supervisory Board, LfA Förderbank Bayern, as Director-Management Board, BayernLB Holding AG, as Director, GTU Geothermie Unterschleißheim AG, as Director-Supervisory Board from 2010 to 2012, and Baader Bank AG, as Member-Supervisory Board from 2010 to 2018.

Nikolai Kley is the founder of two companies, FORMA Therapeutics, Inc. (founded in 2008) and Orionis Biosciences, Inc. (founded in 2015).
At FORMA Therapeutics, he held the title of VP-Biology & Head-Drug Discovery Research from 2008 to 2011.
At Orionis Biosciences, he held the titles of President, Chief Executive Officer & Director from 2015 to present, and currently holds the titles of Managing Director & Director at Orionis Biosciences BV since 2015 and Professor at Princeton University.
He previously worked at Bristol Myers Squibb Co. as a Principal, GPC Biotech AG as a Vice President, The General Hospital Corp.
as a Fellow, Genome Therapeutics Corp.
as a Vice President, and Harvard Medical School as a Fellow.
He received his undergraduate degree from the University of Leeds and doctorate degrees from Max-Planck-Institute for Molecular Genetics and Ludwig-Maximilians-Universität München.

Mr. Jason B.
Kley is Senior Integrated Wealth Advisor at Carlson Capital Management, Inc. He is a member of the Minnesota Financial Planning Association.
Before joining the CCM, Mr. Kley worked for a Minneapolis wealth management firm where he served as a financial advisor, investment committee member, and 401k plan specialist.
Prior to that, he worked for Thrivent Financial and Union Pacific, serving in business analyst and strategic operational roles.
Mr. Kley has also served on the Minneapolis Regional Chamber of Commerce DRIVE Emerging Leaders Board, Best Prep’s Minnesota Business Venture Advisory Committee, and the City of St. Louis Park Police Advisory Commission.
He holds a Bachelor of Arts degree in Math and Computer Science from the University of St. Thomas where he graduated magna cum laude in 1998.
He also earned an MBA with an emphasis in Finance and Strategy from Washington University in St. Louis, Missouri.